EICHORCondition: Oropharyngeal Squamous Cell Carcinoma · Sponsor: University of Florida
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).
This description comes directly from the study's public registry record.
Teresa Ware, MPH · 352-273-5739 · PMO@cancer.ufl.edu
Always discuss trial participation with your own doctor first.
| University of Florida | Gainesville, Florida, United States | Recruiting |
| UF Health Proton Therapy Institute | Jacksonville, Florida, United States | Recruiting |
| Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05268614